Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Englitazone SCHEMBL20125577 | 1.00 | PPARG (0.50) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| Englitazone SCHEMBL4727851 | 1.00 | PPARG (0.50) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| Englitazone SCHEMBL20125579 | 1.00 | PPARG (0.50) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| Englitazone SCHEMBL29377687 | 1.00 | PPARG (0.50) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| Englitazone SCHEMBL9367929 | 0.99 | PPARG (0.49) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| Englitazone SCHEMBL22607925 | 0.99 | PPARG (0.49) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| Englitazone SCHEMBL8522765 | 0.99 | PPARG (0.49) | PPARGFFAR1ALDH1A1NPSR1MAPT | |
| SCHEMBL9665642 | 0.92 | FFAR1 (0.59) | PPARGFFAR1ALDH1A1MAPTPPARA | |
| SCHEMBL9664758 | 0.91 | FFAR1 (0.58) | PPARGFFAR1ALDH1A1MAPTPPARA | |
| SCHEMBL6903859 | 0.89 | PPARG (0.52) | PPARGFFAR1ALDH1A1NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11466 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250332101-A1 | Composition | CORDEIRO MARIA FRANCESCA (GB) | 2025-10-30 | — | — | US | claimed |
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-09-11 | — | — | US | claimed |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD (IL) | 2025-07-10 | — | — | US | claimed |
| WO-2025136060-A1 | CULTURE MEDIUM COMPOSITION FOR TRANSDIFFERENTIATION OF MUSCLE STEM CELLS INTO ADIPOCYTES, AND METHOD FOR PRODUCING CULTURED MEAT BY USING SAME | 한화솔루션 주식회사 | 2025-06-26 | — | — | WO | claimed |
| CN-119698279-A | Treatment of gastrointestinal disorders | 阿克里普斯二有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119613391-A | Engliptin clean purification process | 浙江大学衢州研究院 | 2025-03-14 | — | — | CN | claimed |
| EP-4520343-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-03-12 | — | — | EP | claimed |
| WO-2025049710-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE DISEASE TREATMENTS | ACLIPSE TWO INC. (US) | 2025-03-06 | — | — | WO | claimed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | claimed |
| US-5594015-A | Thiazolidine derivatives for the treatment of psoriasis | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-14 | — | — | US | claimed |
| CN-1134669-A | Use of thiazolidinediones to prevent or delay onset of non-insulin dependent diabetes mellitus (NIDDM) | SANKYO CO (JP) | 1996-10-30 | — | — | CN | claimed |
| EP-0719140-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | Sankyo Company Limited (JP) | 1996-07-03 | — | — | EP | claimed |
| WO-1995035108-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT OF PSORIASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-12-28 | — | — | WO | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |
| EP-0207605-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1990-02-07 | — | — | EP | claimed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | claimed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | claimed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | claimed |